Global Information
회사소개 | 문의 | 위시리스트

암 면역진단 시장 예측과 분석 : 바이오마커를 둘러싼 경쟁

Immuno-Oncology Diagnostics, The Race for Biomarkers, Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024

리서치사 Howe Sound Research
발행일 2019년 10월 상품 코드 804234
페이지 정보 영문 277 Pages
가격
US $ 6,995 ₩ 8,361,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,545,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,729,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



암 면역진단 시장 예측과 분석 : 바이오마커를 둘러싼 경쟁 Immuno-Oncology Diagnostics, The Race for Biomarkers, Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024
발행일 : 2019년 10월 페이지 정보 : 영문 277 Pages

세계의 암 면역진단(Immuno-Oncology Diagnostics) 시장에 대해 조사했으며, 면역요법 기술 가이드, 산업 개요, 시장 성장 영향요인, 기술 개발 동향, 최근의 발전 동향, 세계 시장 규모, 종류별 시장 및 주요 기업 등에 대해 분석했습니다.

제1장 서론·시장 정의

제2장 면역요법 : 면역 기술 가이드

  • 면역 시스템
    • 선천성 면역 시스템
    • 적응 면역 시스템
    • 면역 종양햑
  • 암 면역진단
    • 체크포인트 어세이
    • 사이토카인(Cytokine) 어세이
    • 생식세포 계열 게놈
    • 암 게놈
    • 종양미세환경(Tumor Microenviroment)
    • 기타

제3장 산업 개요

  • 동적 시장에서의 기업/연구소 등

제4장 시장 동향

  • 성장 촉진요인
  • 성장 억제요인
  • 진단기술 개발

제5장 암 면역요법의 발전 동향

  • 최근의 발전 : 중요성과 이용법

제6장 주요 면역요법 기업 개요

  • 10X Genomics
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • bioMerieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako(Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

제7장 세계 시장 규모

  • 세계 암 면역진단 시장 규모 : 국가별, 도표 첨부
  • 세계 암 면역진단 시장 규모 : 종류별, 도표 첨부

제8장 세계 시장 : 종류별

  • 체크포인트 어세이 시장
  • 사이토카인(Cytokine) 어세이 시장
  • 생식세포 계열 게놈 시장
  • 암 게놈 시장
  • 종양미세환경 시장
  • 기타 시장

제9장 부록

LSH 19.03.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Table of Tables

  • Table 1 List of Cancers by Mortality
  • Table 2 Lab Spending 2014 to 2024
  • Table 3 Overview of Innate and Adaptive Immunity
  • Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 5 FDA Approved Companion diagnostics in Cancer treatment
  • Table 6 Market Players by Type
  • Table 7 Five Factors Driving Growth
  • Table 8 Three Factors Limiting Growth
  • Table 9 Immuno-oncology Diagnostics Global Market by Country/Region
  • Table 10 Immuno-oncology Diagnostics Global Market by Type
  • Table 11 Checkpoint Assay Market by Country
  • Table 12 Cytokine Assay Market by Country
  • Table 13 Genome Germline Market by Country
  • Table 14 Genome Tumour Market by Country
  • Table 15 Tumour Micro Environment Market by Country
  • Table 16 Other Market by Country

Table of Figures

  • Figure 1 Cancer Death Rates - USA, CDC
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Helper T Cell Roles
  • Figure 4 Antibody Diagram
  • Figure 5 Macrophages attack a Cancer Cell
  • Figure 6 The Tumour Micro Environment
  • Figure 7 Comparing IO Diagnostic and Traditional Testing
  • Figure 8 Growth rates of IO DiagnosticTechnologies
  • Figure 9 Market Size by Country - Key Countries
  • Figure 10 Global Market by Country
  • Figure 11 Chart of Global Market by Type
  • Figure 12 Growth Rates of Diagnostic Segments
  • Figure 13 IO Diagnostics Share Change by Type
  • Figure 14 Chart - Checkpoint Assay Market by Country
  • Figure 15 Chart - Cytokine Assay Market by Country
  • Figure 16 Chart - Genome Germline Market by Country
  • Figure 17 Chart - Genome Tumour Market by Country
  • Figure 18 Chart - Tumour Micro Environment Market by Country
  • Figure 19 Chart - Other Market, Global Size
  • Figure 20 FDA Cancer Drug Approvals by Year
  • Figure 21 Clinical Trials for Immunotherapy by Year
  • Figure 22 Pie Chart of Prevalence of Cancer Treatments

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research Seminar - Burke Institute

Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants
  • iD. Impact of the Nobel Prize

1. Introduction and Market Definition

  • 1.1 What are Immuno-Oncology Diagnostics?
  • 1.2 Immuno-oncology - the looming cure
    • 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
  • 1.3 Market Definition
    • 1.3.1 Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies

  • 2.0 The Immune System
    • 2.0.1 Innate immune system
      • 2.0.1.1 Surface barriers
      • 2.0.1.2 Inflammation
      • 2.0.1.3 Complement system
      • 2.0.1.4 Cellular barriers
      • 2.0.1.5 Natural killer cells
    • 2.0.2 Adaptive immune system
      • 2.0.2.1 Lymphocytes
      • 2.0.2.2 Killer T cells
      • 2.0.2.3 Helper T cells
      • 2.0.2.4 Gamma delta T cells
      • 2.0.2.5 B lymphocytes and antibodies
    • 2.0.3 Tumor immunology - the immune surveillance system
  • 2.1 Immuno OncologyDiagnostics
    • 2.1.1 Checkpoint Assays
      • 2.1.1.1 Outlook for Checkpoint Assays
    • 2.1.2 Cytokine Assays
      • 2.1.2.1 Outlook for Cytokine Assays
    • 2.1.3 Genomic Germline
      • 2.1.3.1 Outlook for Genomic Germline
    • 2.1.4 Genomic Tumour
      • 2.1.4.1 Outlook for Genomic Tumour
    • 2.1.5 Tumor Microenviroment
      • 2.1.5.1 Outlook for Tumor Micro Environment
    • 2.1.6 Others
      • 2.1.6.1 Outlook for Other Diagnostics

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Genomic Instrumentation Supplier
      • 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 3.1.4 Pharmaceutical/Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Lab
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Outcome potential
    • 4.1.2 Companion Diagnostics
    • 4.1.3 Funding
    • 4.1.4 Technology Environment
    • 4.1.5 Target Solutions
  • 4.2 Factors Limiting Growth
    • 4.2.1 Complex Role of Diagnostics
    • 4.2.2 Clinical Trials Role
    • 4.2.3 Protocols
  • 4.3 Diagnostic Technology Development
    • 4.3.1 Combinations - Issues and Complexity
    • 4.3.2 Shifting Role of Diagnostics
    • 4.3.3 Multiplexing and Foundation One
    • 4.3.4 The Disruption Dynamic
    • 4.3.5 The Race for Biomarkers
    • 4.3.6 The Next Five Years

5. Cancer Immunotherapy Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
      • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
      • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
      • Generex to Merge with NuGenerex Immuno-Oncology
      • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies
      • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative Breast Cancer
      • Icon Acquires MolecularMD
      • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
      • Tumor Mutational Burden as Predictor of Immunotherapy Success
      • Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
      • Abcam Acquires Calico Biolabs
      • Cancer Genetics and NovellusDx to Merge
      • ApoCell Expands Immuno-Oncology Biomarker Services
      • MRM Proteomics Inc and Exactis Innovation Partner
      • Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
      • Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
      • Immuno-Oncology Diagnostics 2020 to 2024
      • MolecularMD Launches Validated Tumor Mutation Burden Assay
      • Minomic Secures Key Patent in the United States and China
      • Biocartis and Wondfo Announce Joint Venture
      • Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics
      • Cancer Genetics Expands Immuno-Oncology Panel
      • 10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product
      • Qiagen, Freenome Partner to Improve Companion Diagnostic Development
      • Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime
      • Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio
      • Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies
      • HalioDx announces high capacity IHC multiplex technology
      • MolecularMD to Implement Promega's Technology
      • NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel
      • MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response
      • Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC
      • HalioDx Closes €18.5M Series B Round
      • Announcement of the 2018 Nobel Prize in Physiology or Medicine

6. Profiles of Key Immunotherapy Companies

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioM??rieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

7. Global Market Size

  • 7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts
  • 7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts

8. Global Market by Type

  • 8.1 Checkpoint Assay Market
    • 8.1.1 Checkpoint Assay Market by Country with Chart
  • 8.2 Cytokine Assay Market
    • 8.2.1 Cytokine Assay Market by Country with Chart
  • 8.3 Genome Germline Market
    • 8.3.1 Genome Germline Market by Country with Chart
  • 8.4 Genome Tumour Market
    • 8.4.1 Genome Tumour Market by Country with Chart
  • 8.5 Tumour Micro Environment Market
    • 8.5.1 Tumour Micro Environment Market by Country with Chart
  • 8.6 Other Market
    • 8.6.1 Other Market by Country with Chart

9. Appendices

  • 9.1 FDA Cancer Drug Approvals by Year
  • 9.2 Clinical Trials Started 2010 to 2016
  • 9.3 Prevalence of Cancer Treatments - 2015
Back to Top
전화 문의
F A Q